Physician profile
Jane Syriac
NPI 1336175512
$7,460.82
in general payments reported to CMS, 2019-2025
33 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $1,366 · 2021: $1,552 · 2022: $1,312 · 2023: $1,310 · 2024: $898 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,418.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $914.81 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $838.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $770.52 | 2019-2024 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $761.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $542.91 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $524.09 | 2019-2022 | |
| Abbvie INC. | $510.40 | 2021-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $437.89 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.98 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $169.13 | 2019-2022 | |
| Allergan, INC. | $126.67 | 2019-2020 | |
| Radius Health, INC. | $119.12 | 2019-2023 | Tymlos |
| Abbott Laboratories | $114.76 | 2022-2024 | Freestyle Libre 2 |
| Exact Sciences Corporation | $114.55 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $111.50 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.74 | 2020-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $95.04 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $94.56 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.35 | 2019-2024 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $87.21 | 2021 | |
| Currax Pharmaceuticals LLC | $84.64 | 2023-2024 | Contrave, Nexletol, Nexlizet |
| Sanofi-Aventis U.S. LLC | $76.78 | 2020-2021 | |
| Horizon Therapeutics Plc | $64.76 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.72 | 2023 | |
| Endo Pharmaceuticals INC. | $46.53 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.25 | 2021-2022 | |
| Astellas Pharma US INC | $37.64 | 2019 | |
| Vivus LLC | $30.11 | 2019-2024 | Qsymia |
| Evoke Pharma, INC. | $25.49 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $22.06 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.14 | 2023 | Quviviq |
| Alfasigma USA, INC. | $16.92 | 2022 | |
| Sanofi Pasteur INC. | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Syriac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.